PT3620176T - Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico - Google Patents

Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico

Info

Publication number
PT3620176T
PT3620176T PT192059806T PT19205980T PT3620176T PT 3620176 T PT3620176 T PT 3620176T PT 192059806 T PT192059806 T PT 192059806T PT 19205980 T PT19205980 T PT 19205980T PT 3620176 T PT3620176 T PT 3620176T
Authority
PT
Portugal
Prior art keywords
anticholinergic
corticosteroid
adrenergic
beta
preparing
Prior art date
Application number
PT192059806T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3620176(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PT3620176T publication Critical patent/PT3620176T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PT192059806T 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico PT3620176T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16

Publications (1)

Publication Number Publication Date
PT3620176T true PT3620176T (pt) 2021-09-28

Family

ID=54548062

Family Applications (3)

Application Number Title Priority Date Filing Date
PT192059806T PT3620176T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
PT168019826T PT3377108T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
PT192059368T PT3628331T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT168019826T PT3377108T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
PT192059368T PT3628331T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico

Country Status (36)

Country Link
US (4) US10086004B2 (enExample)
EP (3) EP3377108B1 (enExample)
JP (1) JP6963548B2 (enExample)
KR (1) KR20180082443A (enExample)
CN (1) CN108289962B (enExample)
AR (1) AR106688A1 (enExample)
AU (1) AU2016356858B2 (enExample)
CA (1) CA3005290A1 (enExample)
CL (1) CL2018001298A1 (enExample)
CO (1) CO2018005141A2 (enExample)
CY (3) CY1123042T1 (enExample)
DK (3) DK3628331T3 (enExample)
EA (1) EA037716B1 (enExample)
ES (3) ES2891073T3 (enExample)
GE (1) GEP20207157B (enExample)
HR (3) HRP20211598T1 (enExample)
HU (3) HUE056260T2 (enExample)
IL (1) IL259329B (enExample)
LT (3) LT3377108T (enExample)
MA (3) MA50487B1 (enExample)
MD (3) MD3377108T2 (enExample)
ME (1) ME03778B (enExample)
MX (1) MX379853B (enExample)
MY (1) MY186229A (enExample)
PE (1) PE20181488A1 (enExample)
PH (1) PH12018501022A1 (enExample)
PL (3) PL3377108T3 (enExample)
PT (3) PT3620176T (enExample)
RS (3) RS62404B1 (enExample)
SA (1) SA518391570B1 (enExample)
SG (2) SG10201912093YA (enExample)
SI (3) SI3620176T1 (enExample)
TW (1) TWI731891B (enExample)
UA (1) UA125019C2 (enExample)
WO (1) WO2017085004A1 (enExample)
ZA (1) ZA201803168B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
KR20220155609A (ko) 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
EP3947338A4 (en) * 2019-03-27 2023-01-04 Kemin Industries, Inc. METHODS FOR PREPARING METAL CARBOXYLATES IN A MONOTOPE REACTION
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12178782B2 (en) * 2021-03-24 2024-12-31 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
CA2785321C (en) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
CN102946868B (zh) * 2010-06-22 2014-10-29 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
HUE051394T2 (hu) * 2012-12-06 2021-03-01 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista aktivitással rendelkezõ vegyületek
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT3019153T (pt) 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação

Also Published As

Publication number Publication date
PE20181488A1 (es) 2018-09-18
SG10201912093YA (en) 2020-02-27
SG11201804050QA (en) 2018-06-28
AR106688A1 (es) 2018-02-07
HUE049751T2 (hu) 2020-10-28
CY1124490T1 (el) 2022-07-22
EP3377108A1 (en) 2018-09-26
BR112018009807A8 (pt) 2019-02-26
EP3628331A1 (en) 2020-04-01
EA037716B1 (ru) 2021-05-13
DK3620176T3 (da) 2021-09-20
SI3628331T1 (sl) 2021-11-30
AU2016356858B2 (en) 2021-06-24
EA201890966A1 (ru) 2018-11-30
MA50488B1 (fr) 2021-09-30
PL3377108T3 (pl) 2020-09-07
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
NZ742474A (en) 2024-11-29
ME03778B (me) 2021-04-20
US20170136035A1 (en) 2017-05-18
MA43256B1 (fr) 2020-05-29
MX2018005977A (es) 2018-08-29
SI3377108T1 (sl) 2020-05-29
US20200368252A1 (en) 2020-11-26
US20210177866A1 (en) 2021-06-17
US10086004B2 (en) 2018-10-02
US20180360849A1 (en) 2018-12-20
HRP20211600T1 (hr) 2022-01-21
DK3377108T3 (da) 2020-04-20
CO2018005141A2 (es) 2018-09-28
RS62506B1 (sr) 2021-11-30
MA50488A (fr) 2021-05-19
EP3620176B1 (en) 2021-08-11
US11628175B2 (en) 2023-04-18
IL259329B (en) 2020-10-29
LT3628331T (lt) 2021-11-10
HUE056441T2 (hu) 2022-02-28
CA3005290A1 (en) 2017-05-26
IL259329A (en) 2018-07-31
MA43256A (fr) 2018-09-26
MY186229A (en) 2021-06-30
CY1123042T1 (el) 2021-10-29
LT3377108T (lt) 2020-07-10
RS60171B1 (sr) 2020-05-29
PT3377108T (pt) 2020-04-08
CN108289962A (zh) 2018-07-17
PL3620176T3 (pl) 2021-11-22
ES2895687T3 (es) 2022-02-22
TW201722404A (zh) 2017-07-01
SI3620176T1 (sl) 2021-11-30
JP2019501876A (ja) 2019-01-24
ZA201803168B (en) 2019-07-31
MA50487A (fr) 2021-04-28
MD3628331T2 (ro) 2021-12-31
PL3628331T3 (pl) 2021-11-08
BR112018009807A2 (pt) 2018-11-06
HRP20200537T1 (hr) 2020-06-26
TWI731891B (zh) 2021-07-01
EP3628331B1 (en) 2021-08-11
CL2018001298A1 (es) 2018-09-14
GEP20207157B (en) 2020-10-12
US10772896B2 (en) 2020-09-15
KR20180082443A (ko) 2018-07-18
EP3620176A1 (en) 2020-03-11
MX379853B (es) 2025-03-11
DK3628331T3 (da) 2021-09-27
ES2891073T3 (es) 2022-01-26
WO2017085004A1 (en) 2017-05-26
EP3377108B1 (en) 2020-02-19
UA125019C2 (uk) 2021-12-29
HUE056260T2 (hu) 2022-02-28
MA50487B1 (fr) 2021-09-30
SA518391570B1 (ar) 2022-03-27
MD3377108T2 (ro) 2020-07-31
PH12018501022B1 (en) 2018-12-17
PH12018501022A1 (en) 2018-12-17
AU2016356858A1 (en) 2018-05-31
US10966991B2 (en) 2021-04-06
ES2783855T3 (es) 2020-09-18
RS62404B1 (sr) 2021-10-29
CY1124475T1 (el) 2022-07-22
JP6963548B2 (ja) 2021-11-10
HRP20211598T1 (hr) 2022-01-07
CN108289962B (zh) 2021-09-14
PT3628331T (pt) 2021-10-20

Similar Documents

Publication Publication Date Title
PT3620176T (pt) Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
BR112016021834A2 (pt) Copolímero de propileno heteroplástico, processo para preparação de um copolímero de propileno heteroplástico, e, artigo
UY4610S (es) Tapones (para botellas)
PT3393744T (pt) Método para formar um artigo
ZA201803167B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
BR112017025267A2 (pt) recipiente e invólucro seletivamente formado e ferramentas e método associado para fornecer os mesmos
PT3180295T (pt) Processo para rápida humificação e bioestabilização
FR3037106B1 (fr) Turbomachine d’aeronef
BR112016015379A2 (pt) Processo para preparar um óxido de alquileno
ES1199310Y (es) Conjunto para teleconsulta
BR112017023742A2 (pt) processo melhorado para a preparação de compostos anfifílicos de imidazolínio.
IT201600128339A1 (it) Processo wrappatura materiali
TH1601000099A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด